Investor Relations

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
Press Releases
Jun 05, 2024
NEW YORK , June 05, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other
May 14, 2024
Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American Thoracic Society (ATS) AACR presentation reported MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models NEW YORK , May
Corporate Presentation

SEC Filings

Form Description Filing date View
SC 13G

A statement of beneficial ownership of common stock by certain persons

View HTML
SC 13G

A statement of beneficial ownership of common stock by certain persons

View HTML
S-1/A

Amended Registration statement for face-amount certificate companies

View HTML
4/A

Amendment to a previously filed 4

View HTML

Data provided by Kaleidoscope.